← Back to Search

Glucan Synthase Inhibitor

Ibrexafungerp for Histoplasmosis (FURI Trial)

Phase 3

Waitlist Available

Research Sponsored by Scynexis, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 42, day 84

Awards & highlights

FURI Trial Summary

This trial will test a new drug, ibrexafungerp, for people with a fungal disease who haven't responded to other treatments. The drug's safety and effectiveness will be evaluated.

Eligible Conditions

Histoplasmosis
Invasive Candidiasis
Valley Fever
Oral Thrush
Blastomycosis
Chronic Pulmonary Aspergillosis
Allergic Bronchopulmonary Aspergillosis
Invasive Pulmonary Aspergillosis
Vaginal Yeast Infection
Emerging Fungal Infections

FURI Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 42, day 84

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 42, day 84

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 42, day 84 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assessment of Global Response

Secondary outcome measures

Assessment of Recurrence of Baseline Fungal Infection

Assessment of survival

Side effects data

From 2019 Phase 3 trial • 376 Patients • NCT03734991

26%

Diarrhoea

16%

Nausea

Headache

Abdominal pain

Abdominal discomfort

Bacterial vaginosis

100%

80%

60%

40%

20%

Study treatment Arm

Placebo

Ibrexafungerp (SCY-078)

FURI Trial Design

1Treatment groups

Experimental Treatment

Group I: Ibrexafungerp (SCY-078)Experimental Treatment1 Intervention

Ibrexafungerp (SCY-078), orally administered QD for up to 180 days.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ibrexafungerp

2019

Completed Phase 3

~1220

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Scynexis, Inc.Lead Sponsor

17 Previous Clinical Trials

2,245 Total Patients Enrolled

David Angulo, MDStudy DirectorSponsor GmbH

7 Previous Clinical Trials

957 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you share any additional information about other Ibrexafungerp research projects?

"Ibrexafungerp is being trialled in 85 locations worldwide, with the majority of these studies taking place in Bangalore, Karnataka. Currently, there are 4 active trials for Ibrexafungerp, 3 of which are Phase 3 trials."

Answered by AI

Are there different sites where this clinical trial is taking place?

"This clinical trial is being conducted at Washington University School of Medicine, University of Texas Southwestern Medical Center Dallas, University of Pittsburg Medical Center, and 21 other locations."

Answered by AI

Are people still being enrolled in this experiment?

"The trial, which was originally advertised on 2017-04-01, is still recruiting patients, as is evident on clinicaltrials.gov. The study's administrators made their most recent edit on 2022-07-22."

Answered by AI

What other similar research projects exist?

"Ibrexafungerp is being studied in 4 ongoing global clinical trials. The first trial occurred in 2017 and, since then, 9 more have completed. The initial study, which led to the drug's Phase 3 approval, was sponsored by Scynexis, Inc. and had 200 participants."

Answered by AI

What is the government's stance on Ibrexafungerp?

"Given that this is a Phase 3 trial with available data supporting both efficacy and safety, our team at Power has given Ibrexafungerp a safety rating of 3."

Answered by AI